mRNA Pipeline
Research
Browse:
Our mRNA pipeline shows the progress we’re making on clinical programs currently in development to create mRNA medicines for a wide range of diseases and conditions.
All Categories
Program Indication
ID #
Preclinical Development
Phase 1
Phase 2
Phase 3
Commercial
Moderna rights
Respiratory Vaccines
Adults
COVID-19 vaccine
Spikevax®
Commercial
Moderna rights:Worldwide
COVID-19 vaccineNext-gen
mRNA-1283
Phase 3
Moderna rights:Worldwide
Flu vaccine
mRNA-1010
Phase 3
Moderna rights:Worldwide
RSV vaccineolder adults
mRESVIA®
Commercial
Moderna rights:Worldwide
RSV vaccine18-59 high risk
mRNA-1345
Phase 3
Moderna rights:Worldwide
Flu + COVID vaccine
mRNA-1083
Phase 3
Moderna rights:Worldwide
Pandemic Flu vaccine
mRNA-1018
Phase 2
Moderna rights:Worldwide
RSV + hMPV vaccine
mRNA-1365
Phase 1
Moderna rights:Worldwide
Adolescents and Pediatrics
COVID-19 vaccineadolescents
Spikevax®
Commercial
Moderna rights:Worldwide
COVID-19 vaccinepediatrics (under EUA)
mRNA-1273
Commercial
Moderna rights:Worldwide
RSV vaccinepediatrics
mRNA-1345
Phase 2
Moderna rights:Worldwide
Latent & Other Vaccines
Latent Vaccines
CMV vaccine
mRNA-1647
Phase 3
Moderna rights:Worldwide
EBV vaccineto prevent infectious mononucleosis
mRNA-1189
Phase 2
Moderna rights:Worldwide
EBV vaccineto address long term EBV sequelae
mRNA-1195
Phase 2
Moderna rights:Worldwide
HSV vaccine
mRNA-1608
Phase 2
Moderna rights:Worldwide
VZV vaccine
mRNA-1468
Phase 2
Moderna rights:Worldwide
HIV vaccine
mRNA-1644
Phase 1
Moderna rights:Worldwide (IAVI/others funded)
HIV vaccine
mRNA-1574
Phase 1
Moderna rights:Worldwide (IAVI/BMGF/NIAID and others funded)
Enteric Vaccines
Norovirus vaccine
mRNA-1403
Phase 3
Moderna rights:Worldwide
Norovirus vaccine
mRNA-1405
Phase 2
Moderna rights:Worldwide
Bacterial Vaccines
Lyme disease vaccine
mRNA-1975
Phase 2
Moderna rights:Worldwide
Lyme disease vaccine
mRNA-1982
Phase 2
Moderna rights:Worldwide
Public Health Vaccines
Zika vaccine
mRNA-1893
Phase 2
Moderna rights:Worldwide (BARDA funded)
Nipah vaccine
mRNA-1215
Phase 1
Moderna rights:Worldwide (NIH funded)
Mpox vaccine
mRNA-1769
Phase 1
Moderna rights:Worldwide
Therapeutics
ONCOLOGY - Intismeran autogene
Adjuvant melanoma
mRNA-4157
Phase 3
Moderna rights:50-50 global profit sharing with Merck
Adjuvant NSCLC
mRNA-4157
Phase 3
Moderna rights:50-50 global profit sharing with Merck
Adjuvant NSCLC post neoadjuvant treatment
mRNA-4157
Phase 3
Moderna rights:50-50 global profit sharing with Merck
Renal cell carcinoma (RCC)
mRNA-4157
Phase 2
Moderna rights:50-50 global profit sharing with Merck
Bladder cancer (HR MIUC)
mRNA-4157
Phase 2
Moderna rights:50-50 global profit sharing with Merck
Bladder cancer (HR NMIBC)
mRNA-4157
Phase 2
Moderna rights:50-50 global profit sharing with Merck
Early and late solid tumor
mRNA-4157
Phase 1
Moderna rights:50-50 global profit sharing with Merck
ONCOLOGY - CANCER ANTIGEN THERAPIES
Checkpoint adaptive immune modulation therapy (AIM-T)
mRNA-4359
Phase 2
Moderna rights:Worldwide
Solid tumors
mRNA-4106
Phase 1
Moderna rights:Worldwide
Solid tumors
mRNA-4203
Preclinical Development
Moderna rights:
Rare Disease Therapeutics
Propionic acidemia (PA)
mRNA-3927
Phase 2
Moderna rights:Worldwide
Methylmalonic acidemia (MMA)
mRNA-3705
Phase 2
Moderna rights:Worldwide
Glycogen Storage Disease Type 1a (GSD1a)
mRNA-3745
Phase 1
Moderna rights:Worldwide
Ornithine transcarbamylase deficiency (OTC)
mRNA-3139
Preclinical Development
Moderna rights:Worldwide
Crigler-Najjar Syndrome Type 1 (CN-1)
mRNA-3351
Preclinical Development
Moderna rights:Provided to Institute for Life Changing Medicines (ILCM) free of charge
Cystic fibrosis (CF)
mRNA-3692 / VX-522
Phase 1
Moderna rights:Vertex to pay milestones and royalties